Ainos Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Earnings Release (Form 10-Q) | 16 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Annual Revenue Growth Annually499.0%Target: Sustained double-to-triple digit growth via commercial scaling
AI Nose Commercial Deployments Quarterly1.4KTarget: Up to 20,000 units under industrial-scale roadmap
Cash and Cash Equivalents Quarterly2.8MTarget: Sufficient liquidity to mitigate going concern risk
Watch Items
- Going Concern Risk and Capital RunwayTrigger: Cash reserves falling below $1.0 million without new financingAction: Evaluate further at-the-market (ATM) equity offerings or related-party loans from ASE Test, Inc.
- Nasdaq Stockholders' Equity ComplianceTrigger: Stockholders' equity falling below the $2.5 million minimum requirementAction: Implement capital restructuring, debt-to-equity conversions, or additional share issuances
- Clinical Trial Progress for VELDONATrigger: Delays in clinical milestones for HIV-related oral warts or Sjögren's syndromeAction: Reallocate R&D resources or seek co-development licensing partners to share clinical costs
Research as of 20 Jun 2026